Both Manuka and Non-Manuka Honey Types Inhibit Antibiotic Resistant Wound-Infecting Bacteria

Area of Science:

• Microbiology
• Wound Healing
• Infectious Diseases

Background:

• Postoperative infections represent 20% of hospital-acquired infections annually in the US.
• Antibiotic-resistant bacteria in wounds pose life-threatening complications, with resistance rates up to 65%.
• Manuka honey, FDA-approved for wound treatment, demonstrates antibacterial properties but can be costly and difficult to obtain.

Purpose of the Study:

• To identify alternative, non-Manuka honey types effective against antibiotic-resistant bacteria in wound infections.
• To evaluate the efficacy of various honeys using a method that accounts for non-diffusing bioactive compounds.

Main Methods:

• A honey-plate method was employed to determine the minimum inhibitory concentration (MIC) of different honey types.
• This method was chosen to overcome limitations of agar diffusion assays, particularly for bioactive compounds like polyphenols.

Main Results:

• Several non-Manuka honeys, notably fresh raw Arkansas wildflower honeys, demonstrated comparable bacterial inhibition to Manuka honey.
• Concentrations of 10-30% of these honeys effectively inhibited the growth of highly antibiotic-resistant bacteria, including 'superbugs'.
• No statistically significant difference was observed between Manuka honey and Arkansas wildflower honey in overall bacterial inhibition.

Conclusions:

• Alternative honey types, such as Arkansas wildflower honey, show significant potential for treating antibiotic-resistant wound infections.
• These findings could provide a more accessible and affordable option for wound care in the US, addressing the critical need for new antibiotic strategies.